6 West Hubbard Street
Suite 500
Chicago, IL 60610
Telephone:
312-527-2157
Facsimile:
312-527-4205
|
 |
Thank you for visiting the website of Rakoczy Molino Mazzochi Siwik LLP. We are a full-service litigation and intellectual property law firm, having significant experience working with clients in the pharmaceutical, chemical, and biotechnology industries.
Please use this website to learn more about our firm and the intellectual property laws that affect our clients’ industries. If you have any questions or concerns, or would like to make an appointment to speak with one of our attorneys, please call us at (312) 527-2157 or fill out the form on the Contact Us page, and someone from the firm will be in touch with you shortly. We look forward to hearing from you.
|
|
 |
RMMS Defeats Motion for Preliminary Injunction for Generic Client in Patent Dispute
On April 25, 2006, the U.S. District Court for the District of Arizona issued a 15-page opinion denying a motion for a preliminary injunction against RMMS's client, Prasco, LLC. After briefing and a hearing before the Court, RMMS defeated Plaintiff Medicis Pharmaceutical Corporation's motion, which called for the removal of Prasco's product from the market. As a result, Prasco was able to keep its generic product on the market pending the outcome of the underlying patent litigation against Medicis.
Amongst the leaders in the field of FDA and Hatch-Waxman litigation, Rakoczy Molino Mazzochi Siwik LLP has recently been recognized as one of a select number of law firms involved in the emerging regulatory battle over generic biologics.
Please see "Pressure Rises for FDA, Congress in Latest Drug Duel" by Christine Hines of the Legal Times.
In July 2005, Partner Christine J. Siwik testified before U.S. Senate, Committee on the Judiciary, Subcommittee on Intellectual Property, at a hearing entitled "Perspective on Patents: Harmonization and Other Matters." Presently, both the U.S. Senate and House of Representatives are considering legislation that could significantly change the patent laws. Through her testimony, Ms. Siwik sought to protect the interests of the generic pharmaceutical industry. A copy of Ms. Siwik's written testimony can be found at http://judiciary.senate.gov/hearing.cfm?id=1582.
RMMS Wins Summary Judgment of Non-Infringement for Generic Client in Patent Dispute Involving Pfizer's Blockbuster Prescription Drug Neurontin®.
On August 22, 2005, the U.S. District Court for the District of New Jersey issued two 30-page decisions granting summary judgment on non-infringement for RMMS's generic client, Apotex, on Pfizer's U.S. Patent No. 6,054,482 for Neurontin®, a prescription drug approved to treat seizure and postherpetic neuralgia. In the long-running patent dispute dating back to 1998, RMMS attorneys have successfully obtained judgments for Apotex on all 3 of Pfizer's Neurontin® patents.
|
|